Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangzhi Tongluo is a Traditional Chinese Medicine (TCM) formulation, primarily developed as a soft capsule for the treatment of primary hyperlipidemia, specifically targeting the "qi stagnation and blood stasis" syndrome. Developed by the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, the drug aims to regulate blood lipid levels through the synergistic effects of its botanical components, which traditionally function to invigorate qi, activate blood circulation, and resolve phlegm. It has been evaluated in multicenter, randomized, double-blind clinical trials to assess its efficacy and safety compared to established lipid-lowering agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiangzhi Tongluo.